GlaxoSmithKline, seen as trailing rival Merck in getting a cervical cancer vaccine to market, said it still is in talks with the FDA about submitting its drug Cervarix for approval. GSK had been expected to announce a filing timetable before the end of 2005, while Merck's Gardasil already has been submitted to U.S. and European regulators.

Full Story:
ABC News

Related Summaries